Connect with us

Stocks

4 No-Brainer Dividend Stocks for the End of 2022

The end of the year is usually an excellent time to look for deals. In 2022, a bear market caused by rising interest rates in response to the highest inflation in four decades punished stock prices. A recent reversal in the downward trend has …

The end of the year is usually an excellent time to look for deals. In 2022, a bear market caused by rising interest rates in response to the highest inflation in four decades punished stock prices. A recent reversal in the downward trend has caused a slight recovery. But some stocks that were oversold during the year are still down considerably and potentially undervalued. So it’s an excellent time to review your dividend stocks portfolio tracker and research potential dividend stocks for the end of 2022.

Below we discuss four quality dividend stocks with solid yields and growth with acceptable valuations. We focus on dividend stocks with reliable safety and the potential for long-term returns.

Advertisement

VZ
Verizon
$38.66
PG
Procter & Gamble
$144.49
MSFT
Microsoft
$242.68
MDT
Medtronic
$82.35

Verizon (VZ)

Source: Michael Vi / Shutterstock.com

Advertisement

Verizon (NYSE:VZ) is a stock we have discussed before. But the combination of undervaluation and high dividend yield make it attractive. The stock price has bounced back a bit in the past few weeks but is still down about 26%. Verizon is significantly undervalued based on historical metrics.

The company provides cellular and broadband services to retail and business customers. Verizon serves roughly 120 million wireless connections, 6.7 million FiOS and other broadband connections, and approximately 25 million fixed-line telecom connections. Total revenue was $136 million in the last 12 months, making the firm the second-largest telecommunication company in the United States.

Advertisement

Verizon is paying a 6.8% dividend yield, just below the recent peak and nearly the highest in a decade. The company reliably increases the dividend by 2% annually. It has done so for 18 years, making the stock a Dividend Contender. Moreover, the dividend safety is conservative, with a payout ratio of approximately 47%, alleviating the fear of a dividend cut.

The combination of a bear market and weak retail cellular growth has pressured the stock price while simultaneously increasing the dividend yield and lowering the valuation. Verizon is trading at an earnings multiple of about 7.4x, almost the lowest in the past 10 years. The stock is a good one for investors seeking dividend growth and income.

Advertisement

Procter & Gamble (PG)

Procter & Gamble Union Distribution Center. P&G is an American Multinational Consumer Goods CompanySource: Jonathan Weiss / Shutterstock.com

Procter & Gamble (PG) is one of the most famous Dividend Kings and Dividend Aristocrats. The stock is rarely undervalued. But it is down about 12% in 2022, possibly making it a good time to acquire shares.

Advertisement

The firm sells consumer products globally, operating through five business segments. The five business segments are beauty; grooming; health care; fabric and home care; and baby, feminine and family care. Brands include Tide, Pampers, Charmin, Oral-B, Crest and Old Spice. Most brands are no. 1 or 2 in their market segments. Total revenue was $80.187 million in the fiscal year 2021 and $80.461 million in the past 12 months.

Procter & Gamble has one of the longest dividend streaks over 100 years. Also, it has paid a rising dividend for 66 years, one of only a few companies to achieve the 60-year mark. Additionally, the dividend growth has been slow and steady at roughly 4.9% in the past five years and around 5.2% in the past 10 years. The forward dividend yield is about 2.6%, supported by a reasonable 60% payout ratio. This is near the higher end of our target, but consistent earnings and cash flow limit risk.

Advertisement

Despite the lower stock price in 2022, Procter & Gamble is trading at a price-to-earnings ratio of 24.3x. This value is not a great deal, but it is within the five-year and 10-year ranges. The main interest, though, is low volatility combined with a growing dividend.

Advertisement

Microsoft (MSFT)

the Microsoft (MSFT) logo displayed on smartphone which is laying on top of a keyboard. symbolizes MSFT stock and blue-chip stocksSource: rafapress / Shutterstock.com

Microsoft’s (NASDAQ:MSFT) stock price was caught in the technology sector downdraft. As a result, the stock is down approximately 28% year to date (YTD). But unlike some other tech stocks, Microsoft is wildly profitable and still growing revenue. Moreover, it was not bloated with too many employees, a sign of experienced and prudent management.

Microsoft is a global leader in personal and enterprise software. Also, it sells gaming hardware and tablets. Its major brands include Windows, Outlook, Skype, LinkedIn, SharePoint, Surface, Bing and Xbox. Total revenue was $198.27 million in the fiscal year 2021 and $203.075 million in the past 12 months.

Advertisement

Surprisingly, Microsoft is a dividend growth stock. The company started paying one in 2012 and has raised it each year. The growth rate has been about 13% in the past decade. The modest payout ratio of roughly 29% suggests many more future increases. Microsoft is not a high-yield stock. It currently yields 1%, below the five-year average. However, the main interest is the rock-solid dividend safety supported by an AAA-rated balance sheet and double-digit dividend growth.

The stock is undervalued based on historical ranges. The forward P/E ratio is 25.9x, which seems high. But it is within the five-year and 10-year ranges.

Advertisement

Medtronic (MDT)

Medtronic (MDT) sign outside office building representing healthcare stocksSource: JHVEPhoto / Shutterstock.com

Medtronic (NYSE:MDT) is not as well-known as the three other dividend stocks in this article. But the company is one of the world’s largest medical device companies. The stock price has fallen about 21% in 2022 and is nearing the lows set at the start of the coronavirus pandemic. The company is struggling with higher inflation, a warning letter from the U.S. Food and Drug Administration (FDA) and poor results from a recent medical device trial. That said, the company is high quality.

Advertisement

The company has four business segments: Cardiac and Vascular group (about 36% of total revenue), Minimally Invasive Therapies Group (about 29% of total revenue), Restorative Therapies Group (about 27% of total revenue) and Diabetes Group (about 8% of total revenue). Total revenue was $30.117 million in the fiscal year 2021 and $31.597 million in the last 12 months.

Medtronic is known for its 45-year streak of dividend increases, making the company a Dividend Aristocrat and Dividend Champion. In the trailing five years, the raises have averaged about 8.1%, a respectable amount. Moreover, the forward dividend yield is 3.26%, a decade high. But it is supported by a reasonable payout ratio of about 57% indicating future increases should continue.

Advertisement

The stock price decreases have made Medtronic a deal. It is trading at the lowest valuation in years. The forward P/E ratio is about 15.1x, below the five-year and 10-year ranges. The market expects little from Medtronic, but the impending spinoff should streamline the company.

On the date of publication, Prakash Kolli held LONG positions in VZ, PG, MSFT and MDT. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing GuidelinesThe author is not a licensed or registered investment adviser or broker/dealer. He is not providing you with individual investment advice. Please consult with a licensed investment professional before you invest your money. 

Advertisement

More From InvestorPlace

  • Buy This $5 Stock BEFORE This Apple Project Goes Live
  • The Best $1 Investment You Can Make Today
  • Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

The post 4 No-Brainer Dividend Stocks for the End of 2022 appeared first on InvestorPlace.

InvestorPlace| InvestorPlace

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *